Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirum Pharmaceuticals, Inc.

https://mirumpharma.com

Latest From Mirum Pharmaceuticals, Inc.

First-In-Class Drugs Made Up More Than Half Of US FDA’s Novel Approvals Last Year

CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.

Approvals Drug Approval Standards

First Chinese Rare Disease Biotech IPO To Spark Interest In Less Travelled Path?

CanBridge public listing is expected to generate much needed funding and spotlights a largely untapped but challenging segment.

Rare Diseases Commercial

Rare EU Fast-Track Nod For Sanofi Genzyme's Olipudase Alfa

Only three planned marketing authorization applications are known to have been granted accelerated assessment status by the European Medicines Agency between July and October this year. 

Europe Review Pathway

First-Of Kind BMS Drugs Among Myriad New Filings In EU

Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register